- Home
- CALC vs IGC Comparison
CALC vs IGC Comparison
Compare CALC & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- IGC
- Stock Information
- Founded
- CALC 2011
- IGC 2005
- Country
- CALC United States
- IGC United States
- Employees
- CALC 15
- IGC N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CALC Health Care
- IGC Health Care
- Exchange
- CALC Nasdaq
- IGC Nasdaq
- Market Cap
- CALC 45.4M
- IGC 39.8M
- IPO Year
- CALC N/A
- IGC N/A
- Fundamental
- Price
- CALC $3.23
- IGC $0.41
- Analyst Decision
- CALC Strong Buy
- IGC Strong Buy
- Analyst Count
- CALC 2
- IGC 2
- Target Price
- CALC $14.50
- IGC $4.00
- AVG Volume (30 Days)
- CALC 52.6K
- IGC 727.1K
- Earning Date
- CALC 11-12-2025
- IGC 11-11-2025
- Dividend Yield
- CALC N/A
- IGC N/A
- EPS Growth
- CALC N/A
- IGC N/A
- EPS
- CALC N/A
- IGC N/A
- Revenue
- CALC N/A
- IGC $1,327,000.00
- Revenue This Year
- CALC N/A
- IGC $3.54
- Revenue Next Year
- CALC N/A
- IGC $15.12
- P/E Ratio
- CALC N/A
- IGC N/A
- Revenue Growth
- CALC N/A
- IGC 24.95
- 52 Week Low
- CALC $1.42
- IGC $0.25
- 52 Week High
- CALC $5.65
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CALC 52.57
- IGC 49.66
- Support Level
- CALC $3.13
- IGC $0.38
- Resistance Level
- CALC $3.33
- IGC $0.44
- Average True Range (ATR)
- CALC 0.20
- IGC 0.02
- MACD
- CALC -0.00
- IGC -0.00
- Stochastic Oscillator
- CALC 38.24
- IGC 42.33
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.